Figure 3. Th17 cell phenotype in dLN and mouse brain with or without a GL261 cell injection.

(A) Analysis of draining lymph nodes for CD4⁺IgG2A⁺ (isotype control) or CD4⁺IL-17A⁺ cells in mice that received an intracranial (IC) injection of PBS or 4×10⁵ GL261 cells (Glioma). (B) Analysis of brains for CD4⁺IgG2A⁺ (isotype control) or CD4⁺IL-17A⁺ cells in mice that received an IC injection of PBS or 4×10⁵ GL261 cells (Glioma). (C) Average CD4⁺IL-17A⁺ cell frequency in dLNs or brains (±SEM). (D) Analysis of brains for CD4⁺IL-17A⁺IgG1⁺ (isotype control) or CD4⁺IL-17A⁺IFN-γ⁺ cells (1^st row), CD4⁺IL-17A⁺IgG_2A ⁺ (isotype control) or CD4⁺IL-17A⁺FoxP3⁺ cells (2^nd row) and CD4⁺IL-17A⁺IgG_2B ⁺ (isotype control) or CD4⁺IL-17A⁺IL-4⁺ cells (4^th row) in mice that received an intracranial injection of PBS or 4×10⁵ GL261 cells (Glioma). (E) Average CD4⁺IL-17A⁺IFN-γ⁺, CD4⁺IL-17A⁺FoxP3⁺, and CD4⁺IL-17A⁺IL-4⁺ cell frequency in brains (±SEM). Data are representative of at least 2 independent experiments. * and ** denotes significant differences at p≤0.05 and p≤0.01, respectively.